{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:48:08Z","timestamp":1790801288148,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The fatty acid-binding protein4 (FABP4) and vascular endothelial growth factor A (VEGFA) play key roles in the metabolic and cardiovascular diseases, and proliferative diabetic retinopathy (PDR), respectively. To identify FABP4 in vitreous fluid in PDR, vitreous concentrations of FABP4 (V-FABP4) and VEGFA (V-VEGFA) from PDR (n\u2009=\u200920) and non-PDR (n\u2009=\u200920) patients were determined by Enzyme-Linked ImmunoSorbent Assays. The data, which included height and weight, systemic blood pressures, several blood biochemical parameters and blood flow at the optic nerve head (ONH) by laser speckle flowgraphy (LSFG) were collected. The levels of V-FABP4 and V-VEGFA were significantly higher in PDR patients than in non-PDR patients (P\u2009&lt;\u20090.001) with a high positive correlation (r\u2009=\u20090.72, P\u2009&lt;\u20090.001) between them. The findings were not affected by body mass index values and the presence of vitreous hemorrhaging. Among the clinical parameters, V-FABP4 correlated positively with creatinine and negatively with age and aspartate transaminase (AST) levels, while V-VEGFA correlated positively with fasting plasma glucose and hemoglobin A1c (HbA1c) levels but negatively with AST. Multiple regression analyses indicated that V-VEGFA, or V-FABP4, AST and HbA1c were independent predictors of V-FABP4 or V-VEGFA, respectively. Both were negatively correlated, but more evident in V-FABP4, with the ONH ocular blood flow.<\/jats:p>","DOI":"10.1038\/s41598-021-91857-1","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T10:05:00Z","timestamp":1623405900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Detection of significantly high vitreous concentrations of fatty acid-binding protein 4 in patients with proliferative diabetic retinopathy"],"prefix":"10.1038","volume":"11","author":[{"given":"Kaku","family":"Itoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Hikage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"91857_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.pop.2015.05.005","volume":"42","author":"AM Hendrick","year":"2015","unstructured":"Hendrick, A. M., Gibson, M. V. & Kulshreshtha, A. Diabetic retinopathy. Prim. Care 42, 451\u2013464. https:\/\/doi.org\/10.1016\/j.pop.2015.05.005 (2015).","journal-title":"Prim. Care"},{"key":"91857_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.diabet.2019.04.002","volume":"45","author":"F Semeraro","year":"2019","unstructured":"Semeraro, F. et al. Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications. Diabetes Metab. 45, 517\u2013527. https:\/\/doi.org\/10.1016\/j.diabet.2019.04.002 (2019).","journal-title":"Diabetes Metab."},{"key":"91857_CR3","doi-asserted-by":"publisher","first-page":"e000390","DOI":"10.1136\/bmjophth-2019-000390","volume":"4","author":"J Wirkkala","year":"2019","unstructured":"Wirkkala, J., Bloigu, R. & Hautala, N. M. Intravitreal bevacizumab improves the clearance of vitreous haemorrhage and visual outcomes in patients with proliferative diabetic retinopathy. BMJ Open Ophthalmol. 4, e000390. https:\/\/doi.org\/10.1136\/bmjophth-2019-000390 (2019).","journal-title":"BMJ Open Ophthalmol."},{"key":"91857_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/iae.0000000000001181","volume":"37","author":"JF Arevalo","year":"2017","unstructured":"Arevalo, J. F. et al. Intravitreal bevacizumab for proliferative diabetic retinopathy: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 24 months of follow-up. Retina 37, 334\u2013343. https:\/\/doi.org\/10.1097\/iae.0000000000001181 (2017).","journal-title":"Retina"},{"key":"91857_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","volume":"125","author":"J Figueira","year":"2018","unstructured":"Figueira, J. et al. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study). Ophthalmology 125, 691\u2013700. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.008 (2018).","journal-title":"Ophthalmology"},{"key":"91857_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd2589","volume":"7","author":"M Furuhashi","year":"2008","unstructured":"Furuhashi, M. & Hotamisligil, G. S. Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discovery 7, 489\u2013503. https:\/\/doi.org\/10.1038\/nrd2589 (2008).","journal-title":"Nat. Rev. Drug Discovery"},{"key":"91857_CR7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrendo.2015.122","volume":"11","author":"GS Hotamisligil","year":"2015","unstructured":"Hotamisligil, G. S. & Bernlohr, D. A. Metabolic functions of FABPs: Mechanisms and therapeutic implications. Nat. Rev. Endocrinol. 11, 592\u2013605. https:\/\/doi.org\/10.1038\/nrendo.2015.122 (2015).","journal-title":"Nat. Rev. Endocrinol."},{"key":"91857_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1373\/clinchem.2005.062463","volume":"52","author":"A Xu","year":"2006","unstructured":"Xu, A. et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 52, 405\u2013413. https:\/\/doi.org\/10.1373\/clinchem.2005.062463 (2006).","journal-title":"Clin. Chem."},{"key":"91857_CR9","doi-asserted-by":"publisher","first-page":"e81318","DOI":"10.1371\/journal.pone.0081318","volume":"8","author":"S Ishimura","year":"2013","unstructured":"Ishimura, S. et al. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS ONE 8, e81318. https:\/\/doi.org\/10.1371\/journal.pone.0081318 (2013).","journal-title":"PLoS ONE"},{"key":"91857_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/ajh.2012.88","volume":"25","author":"H Ota","year":"2012","unstructured":"Ota, H. et al. Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am. J. Hypertens. 25, 1124\u20131130. https:\/\/doi.org\/10.1038\/ajh.2012.88 (2012).","journal-title":"Am. J. Hypertens."},{"key":"91857_CR11","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1194\/jlr.M800102-JLR200","volume":"49","author":"A Cabr\u00e9","year":"2008","unstructured":"Cabr\u00e9, A. et al. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J. Lipid Res. 49, 1746\u20131751. https:\/\/doi.org\/10.1194\/jlr.M800102-JLR200 (2008).","journal-title":"J. Lipid Res."},{"key":"91857_CR12","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/atvbaha.107.146274","volume":"27","author":"DC Yeung","year":"2007","unstructured":"Yeung, D. C. et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol 27, 1796\u20131802. https:\/\/doi.org\/10.1161\/atvbaha.107.146274 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol"},{"key":"91857_CR13","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.2174\/0929867325666181008154622","volume":"27","author":"M Shi","year":"2020","unstructured":"Shi, M., Ma, L. & Fu, P. Role of fatty acid binding protein 4 (FABP4) in kidney disease. Curr. Med. Chem. 27, 3657\u20133664. https:\/\/doi.org\/10.2174\/0929867325666181008154622 (2020).","journal-title":"Curr. Med. Chem."},{"key":"91857_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdi.12982","volume":"10","author":"M Furuhashi","year":"2019","unstructured":"Furuhashi, M. et al. Independent links between plasma xanthine oxidoreductase activity and levels of adipokines. J. Diabetes Invest. 10, 1059\u20131067. https:\/\/doi.org\/10.1111\/jdi.12982 (2019).","journal-title":"J. Diabetes Invest."},{"key":"91857_CR15","doi-asserted-by":"publisher","first-page":"R173","DOI":"10.1530\/joe-17-0031","volume":"233","author":"R Rodr\u00edguez-Calvo","year":"2017","unstructured":"Rodr\u00edguez-Calvo, R. et al. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. J. Endocrinol. 233, R173-r184. https:\/\/doi.org\/10.1530\/joe-17-0031 (2017).","journal-title":"J. Endocrinol."},{"key":"91857_CR16","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1021\/bi972520l","volume":"37","author":"PB Kingma","year":"1998","unstructured":"Kingma, P. B., Bok, D. & Ong, D. E. Bovine epidermal fatty acid-binding protein: Determination of ligand specificity and cellular localization in retina and testis. Biochemistry 37, 3250\u20133257. https:\/\/doi.org\/10.1021\/bi972520l (1998).","journal-title":"Biochemistry"},{"key":"91857_CR17","doi-asserted-by":"publisher","first-page":"e0245763","DOI":"10.1371\/journal.pone.0245763","volume":"16","author":"F Hikage","year":"2021","unstructured":"Hikage, F. et al. Fatty acid-binding protein 4 is an independent factor in the pathogenesis of retinal vein occlusion. PLoS ONE 16, e0245763. https:\/\/doi.org\/10.1371\/journal.pone.0245763 (2021).","journal-title":"PLoS ONE"},{"key":"91857_CR18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1755-3768.2009.01586.x","volume":"88","author":"T Sugiyama","year":"2010","unstructured":"Sugiyama, T., Araie, M., Riva, C. E., Schmetterer, L. & Orgul, S. Use of laser speckle flowgraphy in ocular blood flow research. Acta Ophthalmol. 88, 723\u2013729. https:\/\/doi.org\/10.1111\/j.1755-3768.2009.01586.x (2010).","journal-title":"Acta Ophthalmol."},{"key":"91857_CR19","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1097\/iae.0000000000000595","volume":"35","author":"Y Yamada","year":"2015","unstructured":"Yamada, Y. et al. Retinal blood flow correlates to aqueous vascular endothelial growth factor in central retinal vein occlusion. Retina 35, 2037\u20132042. https:\/\/doi.org\/10.1097\/iae.0000000000000595 (2015).","journal-title":"Retina"},{"key":"91857_CR20","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1096\/fj.09-134882","volume":"23","author":"H Elmasri","year":"2009","unstructured":"Elmasri, H. et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 23, 3865\u20133873. https:\/\/doi.org\/10.1096\/fj.09-134882 (2009).","journal-title":"FASEB J"},{"key":"91857_CR21","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","volume":"26","author":"TA Ciulla","year":"2003","unstructured":"Ciulla, T. A., Amador, A. G. & Zinman, B. Diabetic retinopathy and diabetic macular edema: Pathophysiology, screening, and novel therapies. Diabetes Care 26, 2653\u20132664. https:\/\/doi.org\/10.2337\/diacare.26.9.2653 (2003).","journal-title":"Diabetes Care"},{"key":"91857_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.61.2.26","volume":"61","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. Correlation of aqueous, vitreous, and plasma cytokine levels in patients with proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 61, 26. https:\/\/doi.org\/10.1167\/iovs.61.2.26 (2020).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"91857_CR23","doi-asserted-by":"publisher","first-page":"279037","DOI":"10.1155\/2012\/279037","volume":"2012","author":"K Noda","year":"2012","unstructured":"Noda, K., Nakao, S., Ishida, S. & Ishibashi, T. Leukocyte adhesion molecules in diabetic retinopathy. J. Ophthalmol. 2012, 279037. https:\/\/doi.org\/10.1155\/2012\/279037 (2012).","journal-title":"J. Ophthalmol."},{"key":"91857_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40123-017-0083-9","volume":"6","author":"MW Stewart","year":"2017","unstructured":"Stewart, M. W. A review of ranibizumab for the treatment of diabetic retinopathy. Ophthalmol. Ther. 6, 33\u201347. https:\/\/doi.org\/10.1007\/s40123-017-0083-9 (2017).","journal-title":"Ophthalmol. Ther."},{"key":"91857_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.08.001","volume":"51","author":"AW Stitt","year":"2016","unstructured":"Stitt, A. W. et al. The progress in understanding and treatment of diabetic retinopathy. Prog. Retin. Eye Res. 51, 156\u2013186. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.08.001 (2016).","journal-title":"Prog. Retin. Eye Res."},{"key":"91857_CR26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98, 766\u2013785 (1991).","journal-title":"Ophthalmology"},{"key":"91857_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10456-012-9274-0","volume":"15","author":"H Elmasri","year":"2012","unstructured":"Elmasri, H. et al. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: Role of stem cell factor\/c-kit pathway. Angiogenesis 15, 457\u2013468. https:\/\/doi.org\/10.1007\/s10456-012-9274-0 (2012).","journal-title":"Angiogenesis"},{"key":"91857_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000265563","volume":"47","author":"MY Lee","year":"2010","unstructured":"Lee, M. Y., Wang, Y. & Vanhoutte, P. M. Senescence of cultured porcine coronary arterial endothelial cells is associated with accelerated oxidative stress and activation of NFkB. J. Vasc. Res. 47, 287\u2013298. https:\/\/doi.org\/10.1159\/000265563 (2010).","journal-title":"J. Vasc. Res."},{"key":"91857_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.117.006377","author":"T Fuseya","year":"2017","unstructured":"Fuseya, T. et al. Ectopic fatty acid-binding protein 4 expression in the vascular endothelium is involved in neointima formation after vascular injury. J. Am. Heart Assoc. https:\/\/doi.org\/10.1161\/jaha.117.006377 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"91857_CR30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1365-2362.2007.01835.x","volume":"37","author":"M Karpisek","year":"2007","unstructured":"Karpisek, M. et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur. J. Clin. Invest. 37, 637\u2013642. https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01835.x (2007).","journal-title":"Eur. J. Clin. Invest."},{"key":"91857_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12944-016-0177-8","volume":"15","author":"M Furuhashi","year":"2016","unstructured":"Furuhashi, M. et al. Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters. Lipids Health Dis. 15, 5. https:\/\/doi.org\/10.1186\/s12944-016-0177-8 (2016).","journal-title":"Lipids Health Dis."},{"key":"91857_CR32","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1194\/jlr.M059469","volume":"56","author":"M Furuhashi","year":"2015","unstructured":"Furuhashi, M. et al. Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus. J. Lipid Res. 56, 2372\u20132380. https:\/\/doi.org\/10.1194\/jlr.M059469 (2015).","journal-title":"J. Lipid Res."},{"key":"91857_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/hr.2015.2","volume":"38","author":"M Furuhashi","year":"2015","unstructured":"Furuhashi, M. et al. Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. Hypertens. Res. 38, 252\u2013259. https:\/\/doi.org\/10.1038\/hr.2015.2 (2015).","journal-title":"Hypertens. Res."},{"key":"91857_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.neuroscience.2009.02.084","volume":"161","author":"LE Downie","year":"2009","unstructured":"Downie, L. E. et al. Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience 161, 195\u2013213. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.02.084 (2009).","journal-title":"Neuroscience"},{"key":"91857_CR35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1167\/iovs.04-1101","volume":"46","author":"N Nagai","year":"2005","unstructured":"Nagai, N. et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest. Ophthalmol. Vis. Sci. 46, 1078\u20131084. https:\/\/doi.org\/10.1167\/iovs.04-1101 (2005).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"91857_CR36","doi-asserted-by":"publisher","first-page":"9690","DOI":"10.1074\/jbc.M114.626713","volume":"290","author":"A Kanda","year":"2015","unstructured":"Kanda, A., Noda, K. & Ishida, S. ATP6AP2\/(pro)renin receptor contributes to glucose metabolism via stabilizing the pyruvate dehydrogenase E1 \u03b2 subunit. J. Biol. Chem. 290, 9690\u20139700. https:\/\/doi.org\/10.1074\/jbc.M114.626713 (2015).","journal-title":"J. Biol. Chem."},{"key":"91857_CR37","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1021\/pr800112g","volume":"7","author":"BB Gao","year":"2008","unstructured":"Gao, B. B., Chen, X., Timothy, N., Aiello, L. P. & Feener, E. P. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J. Proteome Res. 7, 2516\u20132525. https:\/\/doi.org\/10.1021\/pr800112g (2008).","journal-title":"J. Proteome Res."},{"key":"91857_CR38","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1161\/hypertensionaha.108.127258","volume":"53","author":"C Cousin","year":"2009","unstructured":"Cousin, C. et al. Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 53, 1077\u20131082. https:\/\/doi.org\/10.1161\/hypertensionaha.108.127258 (2009).","journal-title":"Hypertension"},{"key":"91857_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/hr.2010.284","volume":"34","author":"A Yoshikawa","year":"2011","unstructured":"Yoshikawa, A. et al. The (pro)renin receptor is cleaved by ADAM19 in the Golgi leading to its secretion into extracellular space. Hypertens. Res. 34, 599\u2013605. https:\/\/doi.org\/10.1038\/hr.2010.284 (2011).","journal-title":"Hypertens. Res."},{"key":"91857_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa0808400","volume":"361","author":"M Mauer","year":"2009","unstructured":"Mauer, M. et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0808400 (2009).","journal-title":"N. Engl. J. Med."},{"key":"91857_CR41","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/nejm199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello, L. P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480\u20131487. https:\/\/doi.org\/10.1056\/nejm199412013312203 (1994).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91857-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91857-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91857-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:52:17Z","timestamp":1670061137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91857-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91857"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91857-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12382"}}